Breast Cancer Recurrence Survival Among Iranian Patients; A 17-Year Retrospective Cohort Study

Background: Nowadays breast cancer (BC) is the most common cancer in women. More than 1.5 million cases are detected yearly. Survival of patients is dependent on several factors. Metastasis and cancer recurrence of different types and in different locations have various outcome. Methods: This is a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amirreza Ehsani, Nahid Nafissi, Mohammadamin Joulani, Ebrahim Babaee
Formato:	article
Lenguaje:	EN
Publicado:	Kaviani Breast Disease Institute 2021
Materias:	Breast Cancer, Recurrence, Metastasis, Survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/eb998c469e5f43dc87bea60714ff0827
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eb998c469e5f43dc87bea60714ff0827
record_format	dspace
spelling	oai:doaj.org-article:eb998c469e5f43dc87bea60714ff08272021-12-04T02:18:56ZBreast Cancer Recurrence Survival Among Iranian Patients; A 17-Year Retrospective Cohort Study10.32768/abc.202184284-2902383-0433https://doaj.org/article/eb998c469e5f43dc87bea60714ff08272021-10-01T00:00:00Zhttps://www.archbreastcancer.com/index.php/abc/article/view/397https://doaj.org/toc/2383-0433Background: Nowadays breast cancer (BC) is the most common cancer in women. More than 1.5 million cases are detected yearly. Survival of patients is dependent on several factors. Metastasis and cancer recurrence of different types and in different locations have various outcome. Methods: This is a retrospective cohort study to describe survival of patients after diagnosis of breast cancer based on receptor subtypes and sites of metastasis among Iranian population. A total number of 2051 females with breast cancer were evaluated and among these, 138 patients with recurrent BC were investigated. Results: The 1-year survival of local, bone, visceral and brain metastasis were 64.99%, 63%, 32.83%, and 21.57%, respectively. Based on sites of metastasis, bone and local metastasis showed the best survival while brain and visceral metastasis had the worst survival and prognosis. Conclusion: Our study showed that Her2 enriched positive BCs had the worst survival, this may be due to Trastuzumab uncovered insurance till 10 years ago in our country. Also, drugs related to luminal A and B which are used to improve their survival and hormonal therapy could be associated with their better prognosis in comparison to triple negative receptor subtype. But this study showed that triple negative BC had better survival. Amirreza EhsaniNahid NafissiMohammadamin JoulaniEbrahim BabaeeKaviani Breast Disease InstitutearticleBreast Cancer, Recurrence, Metastasis, SurvivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENArchives of Breast Cancer (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Breast Cancer, Recurrence, Metastasis, Survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Breast Cancer, Recurrence, Metastasis, Survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Amirreza Ehsani Nahid Nafissi Mohammadamin Joulani Ebrahim Babaee Breast Cancer Recurrence Survival Among Iranian Patients; A 17-Year Retrospective Cohort Study
description	Background: Nowadays breast cancer (BC) is the most common cancer in women. More than 1.5 million cases are detected yearly. Survival of patients is dependent on several factors. Metastasis and cancer recurrence of different types and in different locations have various outcome. Methods: This is a retrospective cohort study to describe survival of patients after diagnosis of breast cancer based on receptor subtypes and sites of metastasis among Iranian population. A total number of 2051 females with breast cancer were evaluated and among these, 138 patients with recurrent BC were investigated. Results: The 1-year survival of local, bone, visceral and brain metastasis were 64.99%, 63%, 32.83%, and 21.57%, respectively. Based on sites of metastasis, bone and local metastasis showed the best survival while brain and visceral metastasis had the worst survival and prognosis. Conclusion: Our study showed that Her2 enriched positive BCs had the worst survival, this may be due to Trastuzumab uncovered insurance till 10 years ago in our country. Also, drugs related to luminal A and B which are used to improve their survival and hormonal therapy could be associated with their better prognosis in comparison to triple negative receptor subtype. But this study showed that triple negative BC had better survival.
format	article
author	Amirreza Ehsani Nahid Nafissi Mohammadamin Joulani Ebrahim Babaee
author_facet	Amirreza Ehsani Nahid Nafissi Mohammadamin Joulani Ebrahim Babaee
author_sort	Amirreza Ehsani
title	Breast Cancer Recurrence Survival Among Iranian Patients; A 17-Year Retrospective Cohort Study
title_short	Breast Cancer Recurrence Survival Among Iranian Patients; A 17-Year Retrospective Cohort Study
title_full	Breast Cancer Recurrence Survival Among Iranian Patients; A 17-Year Retrospective Cohort Study
title_fullStr	Breast Cancer Recurrence Survival Among Iranian Patients; A 17-Year Retrospective Cohort Study
title_full_unstemmed	Breast Cancer Recurrence Survival Among Iranian Patients; A 17-Year Retrospective Cohort Study
title_sort	breast cancer recurrence survival among iranian patients; a 17-year retrospective cohort study
publisher	Kaviani Breast Disease Institute
publishDate	2021
url	https://doaj.org/article/eb998c469e5f43dc87bea60714ff0827
work_keys_str_mv	AT amirrezaehsani breastcancerrecurrencesurvivalamongiranianpatientsa17yearretrospectivecohortstudy AT nahidnafissi breastcancerrecurrencesurvivalamongiranianpatientsa17yearretrospectivecohortstudy AT mohammadaminjoulani breastcancerrecurrencesurvivalamongiranianpatientsa17yearretrospectivecohortstudy AT ebrahimbabaee breastcancerrecurrencesurvivalamongiranianpatientsa17yearretrospectivecohortstudy
_version_	1718373064120467456

Breast Cancer Recurrence Survival Among Iranian Patients; A 17-Year Retrospective Cohort Study

Ejemplares similares